ICU Medical, Inc. Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Revenue and Earnings: Q3 revenue was $533 million, with 5% organic growth but minus 8% reported year-over-year. Gross margins increased, operating expenses declined, resulting in adjusted EBITDA of $106 million and EPS of $2.03. Free cash flow improved, with $273 million in principal repaid year-to-date.
• Business Segments: Consumables and IV Systems had good year-over-year growth. Vital Care was down due to deconsolidation of IV Solutions. Benefits included a settlement of a portion of the Italian payback liability and deconsolidation of IV Solutions.
• FDA Dialogue: Engaged with the FDA on submissions for the Medfusion 5000, CADD ambulatory pumps, and LifeShield safety software. Vision of a single software solution for infusion pumps to enhance user experience and interoperability.
• Gross Margin: Adjusted gross margin for Q3 was 41%, impacted by a one-time benefit from the Italy medical device payback liability settlement, deconsolidation of IV Solutions, and tariffs. Target of 45% gross margin is being worked towards.
• Outlook: Increased full-year EBITDA guidance to $395 million to $405 million and adjusted EPS guidance to $7.35 to $7.65 per share. Considerations include absence of the Italy settlement benefit in Q4, higher tariff expense, and sequentially higher operating expenses.

Segment Performance

• Consumables: Q3 revenue grew 8% reported and 7% organic, achieving record absolute sales levels. Driven by new global customer implementations, growth in niche markets, and solid census. Contributes to the company's growth.
• IV Systems: Grew 9% reported and 8% organic, with growth across all 3 main product families. LVP pumps and dedicated sets were the largest contributors, with installs from prior quarters pushing into Q3.
• Vital Care: Down 52% reported and 4% organically due to deconsolidation of IV Solutions from the income statement. Critical Care and Respiratory saw slight year-over-year growth.

Guidance

• Increased full-year EBITDA guidance from the prior range of $380 million to $390 million to $395 million to $405 million.
• Adjusted EPS guidance updated from $6.85 to $7.15 per share to $7.35 to $7.65 per share.
• Fourth quarter expected to lack the $4 million benefit from the Italy payback settlement, have higher tariff expense (expected $12 million to $14 million in Q4, total $25 million YTD), and sequentially higher operating expenses. Q4 gross margin expected 40% to 41%, net interest expense ~$19 million, adjusted tax rate 25%, and diluted shares outstanding of 25 million.

Risks

• Tariffs: Impact on gross margin, with $25 million total tariff expense expected for the year.
• FDA Approvals: Uncertainty around approvals for new infusion systems hardware and software, and resolution of warning letters.
• Commercial Execution: Dependence on successful commercial execution to sustain revenue growth and portfolio optimization.

Question and Answer

• **Q: Source of strength in Consumables?

A: Expanded label for Clave, customer wins, growth in niche markets (e.g., oncology, dialysis), and positive performance in international markets like Western Europe.**

• **Q: 2026 tariff exposure?

A: Working on supply chain and manufacturing mitigation efforts, prefer not to annualize the impact, with supply chain efforts in progress.**: Vivek Jain stated they are working on offsetting tariffs but preferred not to focus solely on tariffs.

• **Q: 45% gross margin target and beyond?

A: Focus on technology value, portfolio mix optimization, and financial leverage including capital return through buybacks as leverage ratio improves.**: Vivek Jain discussed the importance of technology value, portfolio mix, and financial strategies for earnings growth.

• **Q: Replacement opportunity in Infusion Systems?

A: Early days for replacement of installed base, with contract perspectives starting in the middle to end of 2026.**: Vivek Jain mentioned replacement opportunities in the pump market are in the early stages, starting mid-next year.

• **Q: Free cash flow and remediation?

A: Free cash flow is an opportunity for value creation, with remediation and restructuring expenses expected to wane over time but not immediately.**: Brian Bonnell noted free cash flow is a value driver, though remediation/restructuring expenses won't drop immediately.